Treatment of high-grade low-stage prostate cancer by high-dose-rate brachytherapy

Journal of Endourology

Volumn 14, Issue 4, 2000, Pages 351-356

  Curran, Michael J ^a   Healey, Glenn A ^a   Bihrle III, William ^a   Goodman, Nancy ^a   Roth, Robert A ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033921687     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2000.14.351     Document Type: Article

References (15)

1. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997;277:1445-1451.
2. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
3. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
4. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-376.
5. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999;281:1598-1604.
6. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-453.
7. Kupelian PA, Katcher J, Levin HS, et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043-1052.
8. Oefelein MG, Grayhack JT, McVary KT. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate. Cancer 1995;76:2535-2542.
9. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
10. Stromberg J, Martinez A, Gonzalez J, et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: Treatment description and preliminary results of a Phase I/II clinical trial. Int J Radiat Oncol Biol Phys 1995;33:161-171.
11. Edmundson GK, Rizzo NR, Teahan M, et al. Concurrent treatment planning for high dose rate prostate template implants. Int J Radiat Oncol Biol Phys 1993;27:1215-1223.
12. 192iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998;41:525-533.
13. Stromberg J, Martinez A, Benson R, et al. Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate indium-192 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 1994;28:67-75.
14. Kovacs G. [Interstitial high dosage irradiation of prostate carcinoma.] (Ger) Ther Umsch 1998;55:429-431.
15. Vijayakumar S, Awan A, Karrison T, et al. Acute toxicity during external-beam radiotherapy for localized prostate cancer: Comparison of different techniques. Int J Radial Oncol Biol Phys 1993;25:359-371.